Latest Breaking News On - Revlimid lenalidomide - Page 4 : comparemela.com

Shares of Cipla rallied 5 per cent to Rs 793 on the BSE on Monday after the pharma company announced the settlement of Revlimid (Lenalidomide) patent litigation with Celgene [Bristol Myers Squibb (BMS)] in the United States. Under the terms of the settlement, Celgene will provide Cipla with a license to sell generic volume-limited amounts of gRevlimid capsules in the US sometime after March 2022 subject to regulatory approval. This limited volume constraint will be applicable till January 2026. The oncology drug, indicated for treatment of multiple myeloma, had annual US sales of $9 billion in CY19 as per a BMS report. Arunesh Verma, CEO, Cipla North America said, “This is an important step forward for us and is in line with our pursuit of improving access to high quality life-saving treatments.”

United statesRevlimid lenalidomideKarunesh vermaCipla north americaOswal securitiesஒன்றுபட்டது மாநிலங்களில்அருனேஷ் வெர்மாசிப்லா வடக்கு அமெரிக்காஒசுவள் பத்திரங்கள்